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Background: Canine vector borne diseases (CVBDs) comprise illnesses caused by a spectrum of pathogens that are
transmitted by arthropod vectors. Some dogs have persistent infections without apparent clinical, hematological or
biochemical abnormalities, whereas other dogs develop acute illnesses, persistent subclinical infections, or chronic
debilitating diseases. The primary objective of this study was to screen healthy dogs for serological and molecular
evidence of regionally important CVBDs.
Methods: Clinically healthy dogs (n = 118), comprising three different groups: Gp I blood donor candidates (n = 47), Gp
II healthy dog volunteers (n = 50), and Gp III stray dogs (n = 21) were included in the study. Serum and ethylenediamine
tetraacetic acid (EDTA) anti-coagulated blood specimens collected from each dog were tested for CVBD pathogens.
Results: Of the 118 dogs tested, 97 (82%) dogs had been exposed to or were infected with one or more CVBD
pathogens. By IFA testing, 9% of Gp I, 42% of Gp II and 19% of Gp III dogs were seroreactive to one or more CVBD
pathogens. Using the SNAP 4DX® assay, Gp I dogs were seronegative for Anaplasma spp., Ehrlichia spp., and B.
burgdorferi (Lyme disease) antibodies and D. immitis antigen. In Gp II, 8 dogs were Ehrlichia spp. seroreactive, 2 were
infected with D. immitis and 1 was B. burgdorferi (Lyme disease) seroreactive. In Gp III, 6 dogs were infected with
D. immitis and 4 were Ehrlichia spp. seroreactive. Using the BAPGM diagnostic platform, Bartonella DNA was PCR
amplified and sequenced from 19% of Gp I, 20% of Gp II and 10% of Gp III dogs. Using PCR and DNA sequencing,
6% of Gps I and II and 19% of Gp III dogs were infected with other CVBD pathogens.
Conclusion: The development and validation of specific diagnostic testing modalities has facilitated more accurate
detection of CVBDs. Once identified, exposure to vectors should be limited and flea and tick prevention enforced.
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Throughout the world, canine vector borne diseases
(CVBDs) are caused by a group of widely distributed and
regionally disparate arthropod borne pathogens. Dogs are
considered competent reservoir hosts for several zoonotic
vector borne bacteria and protozoa, and also serve as an
important source of nutrition for many blood sucking* Correspondence: ed_breitschwerdt@ncsu.edu
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article, unless otherwise stated.arthropods, including fleas, mosquitoes, sand flies and
ticks [1,2]. Importantly, some arthropods are competent
vectors for transmission of more than one CVBD patho-
gen. Also, depending upon geographic location, acaracide
use, life style, and other factors, dogs can be repeatedly ex-
posed to the same or alternatively to multiple different
vectors, ultimately resulting in sequential or concurrent
infection with single or multiple CVBD pathogens [1-4].
Several factors contribute to the relatively high frequency
of co-infections reported in dogs, as compared to other
companion animals or humans from the same geographic
region [1-4]. Collectively, these factors have contributedntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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CVBDs on animal health and welfare, and have facilitated
recent efforts to more thoroughly define public health im-
plications associated with various CVBD pathogens.
Based upon a long evolutionary history and complex
pathogen-vector-host interactions, persistent non-clinical
or occult infection(s) are more prevalent among reservoir
hosts, as compared to accidental hosts. Reservoir hosts tend
to remain outwardly healthy without apparent clinical signs
of illness, often despite concurrent, mild hematological,
biochemical and urinalysis abnormalities. In contrast, ac-
cidental hosts more often develop disease manifestations
that are accompanied by obvious pathophysiological ab-
normalities. Due to variable patterns of disease expression,
ranging from subclinical to life-threatening infections, the
diagnosis and medical management of occult CVBDs
remains challenging. Historically, epidemiological screen-
ing and diagnostic assays were primarily based upon
visualization of CVBD pathogens in patient blood smears
and tissues, and/or serological assays that supported patho-
gen exposure, but by the nature of most assays (antibody
detection) did not confirm active infection. Serology re-
mains an important epidemiological modality to estimate
CVBD prevalences among various dog populations and
can also be used clinically to facilitate patient diagnosis.
With the advent of highly sensitive and specific PCR
assays, researchers and diagnosticians can confirm
CVBD infections by amplification of organism-specific
gene targets, followed by DNA sequencing or another
molecular-based modality [1-3]. Therefore, recent im-
provements to molecular diagnostic techniques allow
for more sensitive screening of non-ill dogs for occult
infections, which facilitates more effective examination of
zoonotic concerns and provides novel insights for the
worldwide management and control of CVBDs. The pur-
pose of this study was to determine the serological and
molecular prevalence of CVBD pathogens in blood donor
candidates, clinically healthy volunteer dogs, and stray
dogs in North Carolina, USA.
Methods
Serum and ethylenediamine tetraacetic acid (EDTA) anti-
coagulated blood specimens were collected from 118 clinic-
ally healthy dogs, representing three different study groups.
Gp I consisted of 47 dogs sampled between July 2009 and
June 2011, that were being screened prior to acceptance as
blood donors at the Veterinary Health Complex, North
Carolina State University. As a component of the blood
donor screening process, complete blood count and urin-
alysis results were available for Gp I dogs. Gp II consisted
of 50 healthy dogs sampled between August 2012 and
March 2013 belonging to veterinary students, technicians,
faculty and local volunteers at the College of Veterinary
Medicine, North Carolina State University who providedblood sample access to their dogs for Institutional Animal
Care and Use Approved research studies (NCSU-IACUC
11-051-0). Prior to sampling, each owner of Gp II dogs
signed an informed consent and completed a brief ques-
tionnaire. Prior to obtaining blood samples, these dogs were
examined by a veterinarian and deemed healthy. Gp III
consisted of 21 stray dogs that were sampled from 2nd
February through 22nd March 2010 at a local animal con-
trol facility. All three dog groups were screened for region-
ally important CVBDs, as described below.
Serology
Serum specimens were tested by immunofluorescent anti-
body (IFA) assays using Bartonella vinsonii subsp. berkhof-
fii (Bvb) genotypes I, II, III, Bartonella henselae (Houston
1 ITS genotype), Bartonella henselae (San Antonio 2
genotype), Bartonella koehlerae, Ehrlichia canis, Babesia
canis, and Rickettsia rickettsii as antigens. The sources of
antigens for these IFA assays have been described previ-
ously [5,6]. Each serum sample was screened at dilutions
of 1:16 to 1:64. All sera that were reactive at 1:64 were
then further tested with two-fold dilutions out to 1:8192.
A cutoff titer of 1:64 was used to define a seroreactive
titer. All serum samples were also screened using a com-
mercial ELISA-based kit (SNAP® 4DX®, IDEXX La-
boratories Inc, Westbrook, ME) for Dirofilaria immitis
antigen, and antibodies to Anaplasma phagocytophilum,
Ehrlichia canis and Borrelia burgdorferi C6 peptide [7].
Bartonella alpha proteobacteria growth medium (BAPGM)
culture
Bartonella spp. BAPGM enrichment blood culture/poly-
merase chain reaction (PCR) was performed as previ-
ously described [8].
Polymerase chain reaction and sequencing
Bartonella intergenic transcribed spacer (ITS) region was
performed targeting the region between the Bartonella 16S -
23S ribosomal RNA genes. Primers and PCR conditions
were previously described [5-6]. Similarly, primers and
PCR conditions for Babesia spp, hemotropic Mycoplasma,
Rickettsia spp, Ehrlichia and Anaplasma were used as pre-
viously described [9-11]. All PCR positive amplicons were
sequenced and consensus sequences were aligned (Vector
NTI Suite 10.1, Invitrogen Corp, CA, USA) with known
sequences in GenBank using the basic local alignment
search tool (BLAST) available from (http://www.ncbi.nlm.
nih.gov/BLAST/). Previously described negative and posi-
tive controls were used for each PCR assay.
Results
Study animals
Gp I blood donor candidates included 28 (60%) male
and 19 (40%) female dogs. The median age was 3 years
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represented, including Greyhound (8), Mixed breed
(8), Terrier (7), German Shepherd (4), Laboratory Re-
triever (4), Golden Retriever (3), Australian Shepherd
(2), Boxer (2), Siberian Husky (2), Belgian Malinois (1),
Chow Chow (1), Doberman (1), English Setter (1),
German Wirehaired Pointer (1), Great Dane (1), and
Walker Hound (1).
Gp II healthy volunteer dogs included 29 (58%) male
and 21 (42%) female dogs. The median age was 4 years
(range – 3 months to 11 years). Seventeen breeds were
represented, including Mixed breed (9), Laboratory
Retriever (9), Terrier (7), Greyhound (4), Australian
Shepherds (4), German Shepherd (4), Beagle (2), Maltese
(2), Boxer (1), Bernese Mountain Dog (1), Border Collie
(1), Corgi (1), Cocker Spaniel (1), German Wirehaired
Pointer (1), Golden Retriever (1), Great Dane (1), and
Mastiff (1). Based upon the questionnaire, 42 (84%) Gp II
dogs were rescued and for the remaining 8 (16%) dogs the
source of origin was not provided. Based on reported ac-
tivities, forty (80%) were classified as indoor dogs, 8 (16%)
were classified as indoor/outdoor and only 2 (4%) as out-
door only. Based on their primary residence, 32 dogs
(64%) were from suburban areas, 10 (20%) were from rural
areas and 8 (16%) from an urban environment. Flea and
heartworm prophylaxis drugs were being administered to
all Gp II dogs at the time of sampling and 47/50 (94%)
dogs received a product for tick control. Based upon the
vector exposure history, flea or tick infestations had oc-
curred in 30 (60%) dogs. Gp III consisted of 13 (62%) male
and 8 (38%) female dogs sampled at a local animal control
facility of which 20% were surrendered by their owners
and 80% were strays. Seven breeds were represented, in-
cluding Mixed breed (10), Labrador Retriever (4), Walker
Hound (2), Pit Bull Terrier (2), Golden Retriever (1),
Australian Shepherd (1) and Beagle (1).
Complete blood count (CBC)
In this study, 70% of the screened blood donors with




















47 4 (9%) 0 0 0 0 0 0 1
Group
II
50 21 (42%) 0 1 0 0 4 0 1
Group
III
21 4 (19%) 0 0 0 0 0 1 0
Legend: Bk – B. koehlerae; BhSA2 – Bartonella henselae San Antonio 2; BhHI– Barton
II, & III; IFA – Immunofluorescent antibody assay; Rr – Rickettsia rickettsii; Ec – Ehrlichexposure or infection had normal CBC values (data not
shown), whereas the remaining dogs had subtle or non-
specific hematological changes.
Serology
Cumulative serology results for the three groups of dogs
are summarized in Table 1.
Group I By IFA testing, 4/47 (9%) blood donor candidate
dogs were seroreactive to one or more CVBD pathogens.
One dog each was E. canis or R. rickettsii seroreactive.
Two dogs were seroreactive for more than 1 IFA antigen
(one dog was R. rickettsii and B. henselae SA2 seroreactive
and another dog was R. rickettsii and Bvb genotype II
seroreactive). No dog was B. canis, B. koehlerae, B. hense-
lae Houston 1, Bvb genotypes I and III seroreactive. SNAP
4DX® results for Anaplasma spp., Ehrlichia spp., and
B. burgdorferi (Lyme disease) antibodies and D. immitis
antigen were negative for all Gp I dogs (Table 1).
Group II With IFA antibody titers greater than or equal
to1:64 considered seroreactive, 21/50 (42%) healthy vol-
unteer dogs were seroreactive to one or more CVBD
antigen, of which 13/21 (62%) were only R. rickettsii sero-
reactive. Based on questionnaire data from the, 21 sero-
reactive dogs, 12 were rescues, 5 obtained from breeders,
and the dog’s origin was not provided for the remaining 4
dogs. Ten of 13 R. rickettsii seroreactive dogs had tick or
flea exposure histories. Three other dogs with histories of
tick or flea exposure were seroreactive to more than one
CVBD pathogen (2 dogs were R. rickettsii and E. canis
seroreactive and one dog was R. rickettsii and Bvb
genotype III seroreactive). All 4 Bvb genotype III sero-
reactive dogs had a history of flea and tick exposure. One
dog was B. henselae Houston 1 seroreactive. No Gp II dog
was B. canis, B. henselae SA2, B. koehlerae, Bvb genotypes
I and II seroreactive by IFA testing. By SNAP 4DX®, 8 dogs
were Ehrlichia spp. seroreactive of which 5 dogs had
a history of tick or flea exposure. Seven of 8 Ehrlichia
spp. seroreactive dogs reportedly received tick controlens
No. of dogs
exposed with
> 1 IFA antigen
SNAP 4DX®





1 0 2 0 0 0 0
3 0 0 3 1 8 0 2
1 0 2 0 4 0 6
ella henselae Houston 1; Bvb – Bartonella vinsonii subsp berkhoffii genotypes I,
ia canis; Bc – Babesia canis.
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and 1 dog with a history of tick or flea exposure was
B. burgdorferi (Lyme disease) seroreactive. No dog was
Anaplasma spp. seroreactive (Table 1).
Group III By IFA testing, 4/21 (19%) dogs sampled at a
local animal shelter were seroreactive. One dog each
was B. koehlerae or E. canis seroreactive. One dog was
B. henselae SA2, E. canis, and R. rickettsii seroreactive.
Another dog was B. henselae SA2 and Bvb genotypes,
I, II and III seroreactive. By SNAP 4DX®, 4 dogs were
Ehrlichia spp seroreactive and 6 dogs were infected with
D. immitis. No dog was seroreactive to Anaplasma spp,
B. canis, B. burgdorferi or B. henselae Houston 1 IFA
antigens (Table 1).
Bartonella spp. BAPGM enrichment blood culture/PCR
platform:
Cumulative BAPGM enrichment blood culture/PCR re-
sults for all three dog groups are summarized in Table 2.
Group I Bartonella DNA was PCR amplified and se-
quenced from the blood of 9/47 (19%) blood donor can-
didate dogs. Prior to BAPGM enrichment blood culture,
B. koehlerae DNA and B. henselae Houston 1 DNA were
PCR amplified and sequenced from blood specimens
from 3 and 1 dog, respectively. After BAPGM enrich-
ment blood culture, B. henselae SA2 DNA was amplified
and sequenced from two additional dogs. Because DNA
sequencing of the 16S-23S ITS amplicon failed, the Bar-
tonella sp. was not determined for three dogs (one dog
was positive by pre-enrichment PCR and the remaining
two dogs by post enrichment PCR). Subculture isolates
were not obtained from any 7 or 14 day BAPGM enrich-
ment cultures (Table 2).
Group II Bartonella DNA was PCR amplified and suc-
cessfully sequenced from the blood of 10/50 (20%)
healthy volunteer dogs. Prior to BAPGM enrichment
blood culture/PCR testing, only one dog was found to
be infected with Bvb genotype III. After BAPGM enrich-
ment blood culture, 9 dogs were infected with Bvb geno-
type II; however, isolates were obtained only from 8
dogs. (Table 2). Based upon questionnaire responses, 6/9
Bvb genotype II culture-positive dogs were either rescues
or strays (3 each), whereas the remaining 3 dogs were
obtained from a breeder. Four Bvb genotype II culture-
positive dogs had a history of flea or tick exposure. Eight
of 9 Bvb genotype II infected dogs reportedly received
flea and tick control prophylaxis.
Group III Bartonella DNA was PCR amplified and se-
quenced from 2/21 (10%) dogs from the local animal
shelter. Prior to BAPGM enrichment blood culture, Bvbgenotype I DNA was amplified and sequenced from the
serum of one dog. After BAPGM enrichment blood cul-
ture, Bvb genotype I was amplified and sequenced from
a second dog and subculture isolates were obtained from
this dog’s 7 and 14 day BAPGM enrichment blood cul-
tures (Table 2).
PCR and sequencing for other CVBD pathogens
Cumulative CVBD pathogen PCR results for all three
groups of dogs are summarized in Table 2.
Group I Three of 47 blood donor candidate dogs (6%)
were M. hemocanis PCR positive. No dog was Babesia
spp., Rickettsia spp, Ehrlichia spp. and Anaplasma spp.
PCR positive (Table 2).
Group II Three dogs (6%) were PCR positive for other
CVBD pathogens, of which two dogs had a history of
flea or tick exposure. E. ewingii DNA was amplified and
sequenced from 2 (4%) dogs and M. hemocanis DNA
was amplified from another dog. No dog was PCR posi-
tive for Babesia spp, Rickettsia spp. or Anaplasma spp.
(Table 2).
Group III Four dogs (19%) were PCR positive, of which
2 were infected with E. ewingii and one dog each was in-
fected with M. hemocanis or Candidatus Mycoplasma
hematoparvum (CMhp). No dog was Babesia spp., Rick-
ettsia spp. and Anaplasma spp. PCR positive (Table 2).
Discussion
This study investigated the serological and molecular
prevalence of regionally recognized CVBDs in blood
donor candidates, clinically healthy volunteer dogs, and
stray or surrendered dogs in central North Carolina.
When serology and PCR results were combined, 97
(82%) dogs had been exposed to or were infected with at
least one CVBD pathogen. Among Gps I, II and III, the
distribution of dogs exposed to or infected with one or
more CVBD pathogens was 34, 90 and 95%, respectively.
Serologically, 42% of the 118 dogs were exposed to more
than one CVBD pathogen. Based upon BAPGM enrich-
ment blood culture/PCR, SNAP 4DX® heartworm anti-
gen, and other CVBD PCR results, 33% of dogs in this
study were actively infected with one or more than one
CVBD pathogen. Despite being considered healthy by
their owners or by the veterinarians obtaining blood sam-
ples for the volunteers and the dogs at the local animal
shelter, the serological and molecular prevalence of
CVBDs in Groups I and II were not substantially different
from CVBD prevalences found in stray or surrendered
dogs sampled at a local humane society. Stray or surren-
dered dogs were more often infected with D. immitis and
exposed to Ehrlichia spp., reflecting frequent exposure to
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spp PCRPre-enrichment PCR Post-enrichment PCR Isolate
Group I 47 9 (19%) Bk (3) BhSA2 (2) 0 3 (6%) Mhc (3) 0 0 0
BhHI (1) Bspp. (2)
Bspp. (1)
Group II 50 10 (20%) Bvb III (1) Bvb II (1) Bvb II (8) 3 (6%) Mhc (1) E. ewingii (2) 0 0
Group III 21 2 (10%) Bvb I (1)† Bvb I (1)* Bvb I (1)* 4 (19%) Mhc (1) E. ewingii (2) 0 0
Bvb I (1)* C Mhp (1)
Legend: Bk – Bartonella koehlerae; BhSA2 – Bartonella henselae San Antonio 2; BhHI– Bartonella henselae Houston 1; Bvb – Bartonella vinsonii subsp berkhoffii genotypes I, II, & III; CVBD – Canine vector borne disease;
† − Bvb genotype I DNA sequence amplified from serum; * - Bvb genotype I DNA sequence amplified from blood; Mhc – Mycoplasma hemocanis; C Mhp- Candidatus M. hematoparvum; Bspp – Bartonella spp;
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heartworm or tick preventive products. Compared to the
other two groups, fewer (9%) blood donor candidate dogs
were seroreactive to a CVBD pathogen, however, 12 (26%)
of these dogs had occult infections with a Bartonella or
hemotropic Mycoplasma spp. Because heartworm pre-
ventive products are routinely administered to most well
cared for, client-owned dogs in North Carolina, no blood
donor candidate was infected with D. immitis. Prior to
expending money to test blood donor candidates for blood
type, general health status and evidence of exposure to or
infection with CVBDs, these dogs were qualitatively
screened by blood bank personnel, potentially selecting
against dogs with historical or frequent vector exposures.
Group II dogs, belonging primarily to NCSU-CVM
personnel or local volunteers were most often exposed to
and/or infected with Bartonella spp., D. immitis, Ehrlichia
spp. and Rickettsia spp., most likely reflecting historical
or more recent exposure to fleas, mosquitoes and ticks.
It is possible that some rescued, local volunteer dogs
had been successfully treated for heartworm disease
(therefore heartworm antigen negative), as this possi-
bility was not addressed in the brief questionnaire
completed by the owners of these canine volunteers. As
determined by questionnaire, veterinary students, techni-
cians, faculty and local volunteers who provide access
to their dogs for clinical studies often adopt rescued or
stray dogs as personal pets. Based upon this study, pet-
adopted, rescued dogs from central North Carolina often
have historical CVBD exposures, which are similar to
the vector exposure/infections found in stray and sur-
rendered dogs. For CVBDs that induce long standing,
occult bloodstream infections, stray and rescued dogs
pose a potential risk if used as blood donors and could
potentially bias laboratory reference ranges and “normal”
reference data, if used as controls in research studies.
Importantly, persistent occult CVBD infections would
bias hematology, chemistry and clinical parameters when
establishing laboratory reference ranges for “healthy” dogs.
Dogs are considered biological hosts for most CVBDs,
but they also serve as important environmental senti-
nels for determining the frequency and distribution of
infected vector populations. For reasons that remain un-
clear, the majority of Rickettsia spp. seroreactive dogs in
the southeastern United States are clinically healthy,
despite the fact that R. rickettsii induces an acute, poten-
tially life-threatening illness in dogs and human patients
accompanied by a high fatality rate. The seroprevalence of
rickettsial antibodies in dogs from endemic regions of the
United States ranges between 26-60% respectively [12].
Following infection of dogs with R. rickettsii in North
America, sterilizing immunity develops in conjunction
with the acute febrile illness [13]. In contrast, dogs in
Europe remain rickettsemic for at least one monthwhen infected with Rickettsii conorii by Rhipicephalus
sanguineus, confirming that dogs are competent reser-
voirs for R. conorii [14]. Seroreactivity to R. rickettsii
antigens was found among all three groups; however,
Rickettsia spp. DNA was not amplified from any clin-
ically healthy dog in this study. There is extensive cross
reactivity among spotted fever group rickettsiae; therefore,
although R. rickettsii was used as the antigen source for
IFA testing, it is not possible to infer which or how many
spotted fever group rickettsiae these dogs might have been
exposed to prior to specimen collection. Surprisingly,
the majority of volunteer dogs (62%) were R. rickettsii
seroreactive, compared to lower prevalences in Groups I
(6.4%) and III (5%). As determined by questionnaire, the
majority of Group II dogs were highly exposed to either
ticks or fleas. Historically, tick transmission of R. rickettsii
in the eastern United States has been attributed solely
to Dermacentor variabilis and in the western United
States to D. andersoni [15-18]. Subsequently, researchers
at the Centers for Disease Control and Prevention (CDC;
Atlanta, GA, USA) documented R. rickettsii transmission
in the southwestern US by Rhiphicephalus sanguineus
(commonly referred to as the brown dog tick or kennel
tick) [17,18]. In this study, dogs that were R. rickettsii
seroreactive were often B. henselae or Bvb seroreactive,
suggesting exposure to a common vector or exposure to
multiple vectors. As there does not appear to be cross re-
activity between Bartonella and Rickettsia spp., these re-
sults may be attributed to simultaneous or sequential
transmission of Bartonella and Rickettsia organisms to
dogs by arthropod vectors [18,19]. A previous serosurvey
study from our laboratory found a statistical association
between seroreactivity to B. henselae and R. rickettsii anti-
gens [20]. B. henselae is transmitted to cats and dogs [21]
by Ctenocephalides felis, the common cat flea, which also
transmits Rickettsia felis [22]. Therefore, it is possible that
the serological association found in current and previ-
ous studies [21,22] reflects flea transmission of both
organisms or alternatively independent exposure to both
fleas and ticks, as B. henselae DNA has also been ampli-
fied from Ixodes spp. ticks in Europe [23] and Ixodes paci-
ficus in North America [24].
Bvb genotypes I, II and III, B. henselae and B. koehlerae
have been documented to infect both dogs and humans
[25-30]. In this study, the overall Bartonella spp. IFA sero-
prevalence was 11% with the majority of seroreactive
dogs found among the volunteer group. Among the six
IFA antigens used in this study, Bartonella spp. seropreva-
lences ranged from 1 to 4%. In contrast, using the BAPGM
diagnostic platform, the overall molecular prevalence of
Bartonella spp. infection was 18%. Of the Bartonella spp.
infected dogs, only 2% were seroreactive to the Bartonella
sp. that was PCR amplified from their blood. A substantial
number of Bartonella sp. bacteremic dogs do not have
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(anergy) occult, host-adapted chronic infection, variation
in antibody reactivity among strains of a Bartonella sp., or
recently transmitted bacteremic infection that is docu-
mented prior to seroconversion. As these dogs were tested
at only one point in time, it is not possible to determine if
these Bartonella sp. infections were acute or chronic. In
naturally-infected dogs, infection with Bvb is known to
cause a prolonged bacteremia spanning months [32] and
following experimental infection, B. henselae persisted for
94 days [33]. Interestingly, the Bartonella spp. detected in
this study varied among groups, with an unexpectedly
high prevalence of occult bacteremia (10-20%) docu-
mented in all three groups. Of those infected, Bvb geno-
type II was found in all but one Gp II dog, whereas only
Bvb genotype I was found in Gp III, and neither genotype
I or II was found in Group I. Previously, infection with
Bvb genotypes I, II and III has been documented in sick
dogs from the southeastern US; however, among sick dogs
B. henselae was the predominant Bartonella sp. docu-
mented [34]. None of the 9 genotype II-infected Group II
dogs were genotype II seroreactive. A recent study by
Yore et al., found DNA of Bvb genotypes I and II in 11.3
and 6.3% of healthy dogs and flea pools in north central
Florida, respectively [35]. The authors suggested that dogs
may serve as a reservoir host for Bvb and fleas (both
C. felis and Pulex sp.) may act as vectors for this pathogen.
In pet dogs, both seroprevalence studies and blood culture
isolation/PCR results indicate infrequent exposure to or
active infection with any of the four Bvb genotypes;
however, seroprevalence is higher in rural and work-
ing dogs, coyotes and feral dog populations [34,36]. As
the 9 Bvb genotype II-infected dogs were sampled for
BAPGM enrichment blood culture/PCR between February
14th and March 7th 2013, exposure to a common vector
cannot be ruled out.
In this study the overall hemotropic Mycoplasma preva-
lence was 5%, with M. hemocanis and Candidatus M.
hematoparvum prevalences of 4% and 1%, respect-
ively. A previous study from our laboratory found an
overall M. hemocanis and Candidatus M. hematopar-
vum prevalence of 1.3% among 506 dogs, with 0.6% of
healthy and 0.8% of sick dogs infected [37]. Subsequently,
Maggi et al. reported the prevalence of hemotropic myco-
plasma infection was significantly greater in veterinarians,
veterinary technicians, spouses of veterinary professionals,
and others with extensive arthropod exposure and/or
frequent animal contact when compared to patients with
less frequent exposures [38]. Also, based upon recent
studies, co-infections with Bartonella and hemotropic
Mycoplasma spp. are commonly found in human patients
[37-40]. In this study, 2 of 3 Gp I blood donor dogs were
co-infected with M. hemocanis and a Bartonella spp.
Thus, evolving evidence supports screening of canineblood donors for hemotropic Mycoplasma and Bartonella
spp. co-infections and further supports the need to deter-
mine if co-infection with these organisms impacts the
health of blood recipient dogs. However, our results can-
not be extrapolated to all geographic regions or to all dog
populations. Dogs that are adopted from environments
that support exposure to heavy flea and tick infestation
should be more intensively screened, before being used
as blood donors. Additional serological and molecular
studies are warranted to determine the prevalence of ex-
posure and infection with CVBDs among diverse popula-
tions of clinically healthy dogs. In addition, greater research
attention should focus on the potential medical import-
ance of hemotropic Mycoplasma and Bartonella spp. co-
infections in animal and human populations.
To prevent the risk of transfusion-associated infec-
tions with CVBD pathogens, blood donors should be
screened prior to acceptance into a blood donor pro-
gram. If not cost prohibitive, comprehensive screening
of canine blood donors to optimally assess CVBD expos-
ure and infection should include serology panels, PCR
panels and the BAPGM enrichment blood culture/PCR
platform. CVBD screening can be tailored to those patho-
gens documented to be endemic, based on geographic
restrictions of disease, breed predilection, and documenta-
tion of disease transmission by transfusion [41]. These
factors have been considered when making donor
screening decisions for various blood donor programs.
Once accepted as a donor, exposure to vectors should be
limited; flea and tick prevention products should be used
routinely; and annual screening should be performed on
all canine blood donors.
Conclusions
CVBD serologic and molecular assays should be used
in combination to screen clinically healthy dogs being
evaluated as potential blood donors or used as con-
trols in biomedical research studies. To prevent future
CVBD infections after initial screening, exposure to
vectors should be strictly limited and acaracide prod-
ucts should be applied routinely and year round to
blood donors and other healthy dogs.Abbreviations
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